We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Decursin and Decursinol Angelate Suppress Adipogenesis through Activation of β-catenin Signaling Pathway in Human Visceral Adipose-Derived Stem Cells.
- Authors
Park, In Sil; Kim, Boyun; Han, Youngjin; Yang, Hee; Cho, Untack; Kim, Se Ik; Kim, Jong Hun; Yoon Park, Jung Han; Lee, Ki Won; Song, Yong Sang
- Abstract
Visceral adiposity is closely associated with metabolic disorders and cardiovascular diseases. Angelica gigas Nakai (AGN) has been reported to possess anti-obesity effects and higher amounts of coumarin compounds are present in AGN. However, the active compounds suppressing adipogenesis in AGN and mechanisms of action have not been investigated in adipose-derived stem cells (ASCs) isolated from visceral adipose tissue (VAT). Among four coumarin compounds of AGN, decursin (D) and decursinol angelate (DA) significantly inhibited adipocyte differentiation from ASCs. D and DA downregulated CCAAT/enhancer binding protein α (C/EBPα), peroxisome proliferator-activated receptor γ (PPARγ), adipocyte fatty acid binding protein (aP2), fatty acid synthase (FAS), and acetyl-CoA carboxylase (ACC) at both mRNA and protein levels. Next, treatment with adipogenic differentiation medium (ADM) on ASCs downregulated β-catenin expression at protein level, while addition of D and DA could restore protein expression and nuclear translocation of β-catenin suppressed by ADM. D and DA treatment on ADM treated ASCs increased inhibitory phosphorylation of Glycogen synthase kinase (GSK)-3β, thereby preventing β-catenin from degradation. Additionally, si-β-catenin transfection significantly upregulated protein expression of C/EBPα and PPARγ, alleviating the anti-adipogenic effect of D and DA on ADM treated ASCs. Overall, D and DA, active compounds from AGN, suppressed adipogenesis through activation of β-catenin signaling pathway in ASCs derived from human VAT, possibly using as natural anti-visceral adiposity agents.
- Subjects
OBESITY complications; ADIPOSE tissues; BENZOPYRANS; CARDIOVASCULAR diseases risk factors; CARRIER proteins; CELL differentiation; CELL physiology; CELLULAR signal transduction; CLINICAL trials; CYTOSKELETAL proteins; ENZYMES; FAT cells; GENE expression; HETEROCYCLIC compounds; MESSENGER RNA; METABOLIC disorders; MOLECULAR structure; OBESITY; PHOSPHORYLATION; PROTEIN kinases; PROTEINS; STEM cells; ANTIOBESITY agents; SIGNAL peptides; DISEASE risk factors; PHARMACODYNAMICS
- Publication
Nutrients, 2020, Vol 12, Issue 1, p13
- ISSN
2072-6643
- Publication type
Article
- DOI
10.3390/nu12010013